Becton, Dickinson and Company $BDX Shares Purchased by Swedbank AB

Key Points

• Swedbank AB increased its holdings in Becton, Dickinson and Company by 9.2%, now owning 168,395 shares valued at approximately $29 million, as per the latest SEC filing.
• Insider transactions revealed that Director Claire Fraser sold 917 shares for over $171,000, resulting in a 3.96% decrease in her ownership in the company.
• Becton, Dickinson and Company recently announced a quarterly dividend of $1.04, representing a 2.2% dividend yield and reflecting a payout ratio of 74.82%.

Swedbank AB lifted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 9.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 168,395 shares of the medical instruments supplier's stock after purchasing an additional 14,205 shares during the quarter. Swedbank AB owned about 0.06% of Becton, Dickinson and Company worth $29,006,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Saudi Central Bank purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $27,000. REAP Financial Group LLC raised its position in shares of Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. Alpine Bank Wealth Management purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $29,000. Finally, Cornerstone Planning Group LLC raised its position in shares of Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 99 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on BDX shares. Morgan Stanley increased their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Piper Sandler reissued a "neutral" rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Barclays reduced their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Finally, Wells Fargo & Company raised their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and an average price target of $213.30.

Becton, Dickinson and Company Trading Down 0.6%

Shares of NYSE BDX traded down $1.10 during trading on Friday, hitting $187.27. 2,750,943 shares of the company were exchanged, compared to its average volume of 1,535,837. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a fifty day moving average price of $187.65 and a 200-day moving average price of $190.16. The firm has a market capitalization of $53.68 billion, a PE ratio of 33.68, a P/E/G ratio of 1.51 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same quarter in the previous year, the firm earned $3.50 EPS. The company's quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's payout ratio is 74.82%.

Insider Activity

In related news, Director Claire Fraser sold 917 shares of the business's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,965 shares of company stock worth $551,536. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.